Willow Biosciences Inc. and SUANFARMA jointly announced execution of a collaboration agreement for a cell line productivity optimization development program for manufacturing a large volume anti-infective Active Pharmaceutical Ingredient (API) through precision fermentation. Through the partnership, SUANFARMA will have access to Willow's proprietary strain optimization technologies to develop a more cost-effective production process. SUANFARMA has engaged Willow to apply its strain engineering technology platform to enable more cost-effective commercial production of the API at SUANFARMA's manufacturing site.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.105 CAD | 0.00% | -16.00% | +5.00% |
1st Jan change | Capi. | |
---|---|---|
+5.00% | 9.8M | |
+8.54% | 100B | |
+11.97% | 43.89B | |
-11.76% | 33.24B | |
+80.16% | 29.36B | |
-12.20% | 16.08B | |
+4.00% | 14.68B | |
-1.90% | 12.87B | |
+178.17% | 10.55B | |
+3.60% | 8.83B |
- Stock Market
- Equities
- WLLW Stock
- News Willow Biosciences Inc.
- Willow Biosciences Inc. and Suanfarma Announce Collaboration on Development of Large Volume Anti-Infective API Through Precision Fermentation